8-K: Pulse Biosciences & MD Anderson Partner on Thyroid Cancer Study

Pulse Biosciences announced a research collaboration with MD Anderson Cancer Center to study its nPulse Vybrance Percutaneous Electrode System for thyroid cancer treatment, with FDA approval for a first-in-human study.

Summary

• Pulse Biosciences, Inc. has initiated a research collaboration with The University of Texas MD Anderson Cancer Center.
• The collaboration will examine the use of the company's nPulse Vybrance Percutaneous Electrode System for the treatment of thyroid cancers.
• The Investigational Device Exemption (IDE) for this first-in-human clinical feasibility study has received approval from the FDA.
• MD Anderson researchers, led by Dr. Victoria Banuchi, will conduct a clinical study to assess the safety and effectiveness of nPulse technology for papillary thyroid microcarcinoma.
• The clinical trial is planned to commence early in 2026, enrolling 30 subjects across two sites.
• Preclinical studies with MD Anderson are ongoing to assess the effect of nsPFA energy on anaplastic thyroid carcinoma, a highly aggressive cancer with a five-year survival rate of less than 5%.
• The nPulse Vybrance Percutaneous Electrode System utilizes Nanosecond Pulsed Field Ablation (nsPFA) energy for precise, nonthermal removal of cellular tissue without damaging noncellular structures or inducing thermal necrosis.
• The system has previously received U.S. Food and Drug Administration (FDA) 510(k) clearance for soft tissue ablation in percutaneous and intraoperative surgical procedures for non-cardiac applications.

Sentiment

Score: 8

Explanation: The announcement of an FDA-approved first-in-human study and a collaboration with a top-tier cancer center for a significant medical need (thyroid cancer) is a strong positive for the company, indicating progress in product development and market expansion.

Positives

• FDA approval of the Investigational Device Exemption (IDE) for a first-in-human clinical feasibility study, marking a significant regulatory milestone.
• Establishment of a research collaboration with The University of Texas MD Anderson Cancer Center, a highly respected institution in cancer research and treatment.
• Expansion of the nPulse technology's potential applications into the treatment of benign and malignant thyroid tumors, addressing a common medical condition.
• The nonthermal mechanism of nsPFA is believed to limit scarring, fibrosis, and damage to critical surrounding structures, potentially offering a superior treatment profile for thyroid tumors.
• Ongoing preclinical studies targeting anaplastic thyroid carcinoma, one of the deadliest types of cancer, indicate pursuit of solutions for high unmet medical needs.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, are beyond Pulse Biosciences' control.
• Actual results may differ materially from those in forward-looking statements due as a result of various factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission.
• Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Future Outlook

Pulse Biosciences expects to carry forward collaborative work to evaluate how its nPulse technology may benefit patients with benign and malignant thyroid tumors. The clinical trial for papillary thyroid microcarcinoma is planned to commence early in 2026. The company is actively pursuing development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Management Comments

• "We believe the nonthermal mechanism of action of nsPFA, which limits scarring, fibrosis, and damage to critical surrounding structures, positions our nPulse technology as potentially the ideal treatment for benign and malignant thyroid tumors."
• "We look forward to carrying this collaborative work forward to evaluate how our game-changing technology may benefit these patients."

Industry Context

This collaboration positions Pulse Biosciences to enter the significant market for thyroid cancer treatment, a common cancer affecting hundreds of thousands of US patients. The focus on a nonthermal ablation method could offer a differentiated approach compared to traditional surgical or thermal ablation techniques, potentially reducing complications like scarring and damage to critical structures. The involvement of a leading cancer center like MD Anderson lends significant credibility and accelerates clinical validation for the nPulse technology.

Comparison to Industry Standards

• The nonthermal mechanism of nsPFA, which limits scarring, fibrosis, and damage to critical surrounding structures, potentially offers an advantage over existing thermal ablation methods or traditional surgery for thyroid tumors.
• Anaplastic thyroid carcinoma, with a five-year survival rate of less than 5%, represents a highly aggressive cancer where new treatment modalities like nsPFA could address a significant unmet medical need, potentially offering a better outcome than current standards of care.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to expanded market opportunities and validation of nPulse technology through a prestigious collaboration and FDA approval.
• Patients: Potential for a new, less invasive, and more effective treatment option for benign and malignant thyroid tumors, particularly for aggressive forms like anaplastic thyroid carcinoma.
• Medical Community: Introduction of a novel nonthermal ablation technology for thyroid cancer, potentially influencing future treatment paradigms and clinical practice.
• Employees: Positive impact on morale and potential for growth as the company expands its clinical programs and market reach.

Next Steps

• Commencement of the clinical study for papillary thyroid microcarcinoma early in 2026.
• Enrollment of 30 subjects across two sites for the clinical study.
• Ongoing preclinical studies with MD Anderson researchers to assess nsPFA energy's effect on anaplastic thyroid carcinoma.
• Continued development of nPulse technology for atrial fibrillation and other markets.

Key Dates

Recommendation

The FDA approval for a first-in-human study and the collaboration with a prestigious institution like MD Anderson Cancer Center for a significant medical application (thyroid cancer) represent substantial validation and market expansion potential for Pulse Biosciences' nPulse technology. This significantly de-risks the technology's development path and opens up a large addressable market, making it a strong positive catalyst for the stock.

Keywords

Pulse Biosciences, nPulse technology, Nanosecond Pulsed Field Ablation, nsPFA, thyroid cancer, MD Anderson Cancer Center, FDA approval, clinical study, medical device, oncology, biotech